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Letters to the Editor
Excess Long-Term Mortality in Patients
With New-Onset Atrial Fibrillation
Following Coronary Artery Bypass Grafting
In a recent report, Villareal et al. (1) presented compelling data in
support of an independent association between new-onset atrial
fibrillation (AF) after coronary artery bypass graft (CABG) surgery
and excessive long-term mortality up to 1,400 days. In the
accompanying editorial, Levy and Kannel (2) correctly caution
readers that this contention is not yet fully substantiated. This is
because of study design and analysis limitations, including 1)
potential residual confounding, and 2) lack of objective data
supporting a plausible mechanism for how AF causes this late
mortality. We have the following additional observations.
First, as partly noted in the editorial (2), entering age as a
categorical variable 65 years is probably inadequate given its
importance for both AF and mortality, which clouds the reported
findings. Indeed, the fact that older age was not found to predict
mortality in either the AF or no-AF cohort (refer to Table 6 in
Villareal et al. [1]) may have been a side product of this method-
ology, and it is particularly surprising given that age65 years was
a highly significant predictor (p  0.0001, OR  2.04; refer to
Table 3 in Villareal et al. [1]) of mortality for all patients combined
(1).
Second, Villareal et al. (1) elaborated on a potential exciting
observation, namely that antiarrhythmic drugs—which were asso-
ciated with a significant 32% reduction in mortality—may have a
yet undefined therapeutic role in improving outcomes in AF
patients. This too was discussed in the editorial (2), but we
contend that this potential role is significantly tempered by the fact
that the derived protective effect of these drugs was identical in AF
and no-AF patients (refer to Table 6 in Villareal et al. [1]). This
presents the following question: If antiarrhythmic therapy im-
proves outcome, shouldn’t their protective effect be more pro-
nounced in the AF population?
Our third observation relates to the fact that the case-matched
groups were distinctly different from either prematching group.
The employed methodology was very briefly described in the
Methods section (1), and it is difficult to ascertain how the
matching was done. Yet, almost always, propensity matching of
patients will lead to matched cohorts with their variable values
intermediate to the two baseline populations. This was not true of
the case-matching used in this study (1), and its implications on
the reported results remain an open question.
The above limitations not withstanding, to the extent that these
long-term findings are true combined with the known substantial
impact of AF on postoperative outcomes and resource utilization,
this report (1) re-emphasizes a) the need to improve the clinical
management of AF during and after hospitalization and, perhaps
more importantly, b) the need to develop prophylactic measures
(including surgical) to minimize its incidence. Accordingly, future
efforts should focus on answering the critical questions: 1) in whom
should prophylactic interventions (e.g., ablation) be done and how
effective are they? and 2) are the associated costs justified?
Finally, the difficulty encountered by the investigators in match-
ing AF patients to their no-AF counterparts—only 195 of 994
(20%) AF patients could be matched despite an abundance of
no-AF (n  5,481) patients—is an interesting yet underdiscussed
aspect. We propose that this difficulty may prove to be a useful
characteristic that may facilitate identification of multivariate
models of high sensitivity and specificity for predicting high-risk
AF patients. Such models may then be used to target prophylactic
interventions toward patients who are most likely to benefit, and to
do so in an objective and cost-effective manner.
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REPLY
We thank Dr. Habib and colleagues for their interest in our study
(1) and deeply appreciate their comments. Our response is both
general and specific.
In general, there will always be residual confounding unless a
study population is randomized. Conversely, in randomized stud-
ies, the “confounding” takes the form of a selection bias dictated by
the usually rigid inclusion and exclusion criteria. The appeal of
observational database studies such as ours lies in the large
population available for study, capturing the influence of real-
world, more current medical practice, the availability of proven
statistical methods to adjust for baseline differences in clinical
characteristics, and a long history of findings utilizing these
methods that predict, are consistent with, and have subsequently
been corroborated by randomized trials. Indeed, the backbone of
current cardiovascular risk assessment—with factors such as age,
gender, diabetes, hypertension, hypercholesterolemia, tobacco use,
and a family history of premature coronary disease—was derived
using similar methodologies.
The comments regarding age, antiarrhythmic drug effect, and
the matching process are well founded, on-the-mark, and are
issues that we too have discussed at length among ourselves. We
are in agreement that these may, at least in part, simply be a
by-product of the methodology, which has not uncommonly been
described as “statistical fishing.” Hence, the caution admonished in
its interpretation. The matching process was an attempt to link as
many of the patient characteristics as possible that predicted
adverse outcomes, while maintaining a “respectable” number of
patients for comparison, which we arbitrarily set at 200. The
difficulty in matching, which involved manually entering and
removing variables from the model without reducing the number
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significantly less than 200, probably resulted in a case-matched
population with significantly different characteristics from the
parent populations. This underscores the difficulty in studying this
particular disease entity, but also suggests that more sensitive and
specific multivariate models can be constructed to better identify
patients at risk.
Overall, notwithstanding the limitations inherent in the meth-
ods and those described above, we believe we have built a strong
case against postoperative atrial fibrillation as a predictor of
mortality. More importantly, we have raised awareness that this is
more than likely not a benign process and that it deserves more
in-depth study.
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Should We Use the Cutting Balloon
in Patients With In-Stent Restenosis?
We read with great interest the elegant randomized study of
Albiero et al. (1) comparing cutting balloon with conventional
balloon angioplasty in a large cohort of patients with in-stent
restenosis (ISR). The researchers found that recurrent restenosis
rate (29.8% vs. 31.4%) and major adverse cardiac events at seven
months (16.4% vs. 15.4%) were similar in the two groups.
In-stent restenosis constitutes a major clinical problem and a
therapeutic dilemma with a high recurrence risk (2). In this
challenging setting, published retrospective studies have consis-
tently demonstrated the favorable outcome provided by different
mechanical strategies that have emerged as attractive alternatives to
conventional balloon angioplasty. Therefore, systematic use of
these specific devices (laser, rotational atherectomy, cutting bal-
loon, and restenting) has been advocated for selected patients with
ISR. Furthermore, such devices have been rapidly embraced by the
interventional cardiology community as the result of their highly
appealing mechanistic properties. Nevertheless, uniformly, all
large-scale randomized trials have been unable to confirm the
suggested benefit of these alternative mechanical interventions
(1,3,4).
In this regard, Albiero et al. (1) should be congratulated for
carrying out the definitive study on the use of cutting balloon in
patients with ISR. The associated procedural-related advantages,
including a lower incidence of balloon slippage, however, remain of
major interest. In a previous study (5) we found that, in patients
with ISR, balloon slippage was associated with poorer acute and
long-term angiographic results. In the study by Albiero et al. (1),
although this phenomenon was not a predictor of restenosis in the
overall patient population, it would have been of great interest to
know the implications (both acute and long-term) of this finding
in patients treated with conventional balloon angioplasty. It is
quite possible that the appearance of this technical problem could
explain suboptimal results or residual dissections and, therefore,
the higher requirement of additional stenting in the balloon group.
Finally, although the cutting balloon was not superior to
conventional dilation in the entire series it would be of major
interest to know whether any specific subgroup of patients bene-
fited from the technique. Despite inherent problems with sub-
group analyses, identification of a subset of ISR patients likely to
benefit from this technique would be of enormous practical value.
Currently, most investigators favor the use of cutting balloon
during brachytherapy procedures to prevent geographical miss and
subsequently edge-restenosis. Nevertheless, once again, a recent
study failed to demonstrate long-term benefits after the use of this
device in ISR patients undergoing brachytherapy (6). Whether the
reported procedural advantages of using cutting balloon will
translate into clinical or angiographic benefit for patients with ISR
treated with drug-eluting stenting (7) remains speculative but
deserves prospective evaluation. Above all, it becomes clear that in
the rapidly evolving field of interventional cardiology the impetus
for adopting new devices, strategies, and ideas should be tempered
and balanced out by the so-called “evidence-based medicine.”
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